Mortality benefit of recombinant human interleukin-1 receptor antagonist for sepsis varies by initial interleukin-1 receptor antagonist plasma concentration

NJ Meyer, JP Reilly, BJ Anderson… - Critical care …, 2018 - journals.lww.com
Objective: Plasma interleukin-1 beta may influence sepsis mortality, yet recombinant human
interleukin-1 receptor antagonist did not reduce mortality in randomized trials. We tested for
heterogeneity in the treatment effect of recombinant human interleukin-1 receptor antagonist
by baseline plasma interleukin-1 beta or interleukin-1 receptor antagonist concentration.
Design: Retrospective subgroup analysis of randomized controlled trial. Setting: Multicenter
North American and European clinical trial. Patients: Five hundred twenty-nine subjects with …